Work

Senolytic drug reduces cancer resistance to PD-L1 blockade

Year: 2026
Type: article
Abstract: Resistance to immune checkpoint inhibitors (ICIs), including anti-PD-L1 therapies, remains a major challenge in cancer treatment, with many patients relapsing despite initial responses. Here, we develop a mathematical model to investigate a mechanism of anti-PD-L1 resistance driven by age-associated senescence of CD8+ T cells, in which senescent T cells (Ts) secrete VEGF, thereby promoting tumor growth through enhanced vascular support. To counteract this effect, we incorporate the senolytic drug navitoclax (ABT-263), which selectively eliminates senescent T cells, and evaluate the efficacy of combined senolytic-anti-PD-L1 therapy in extending tumor remission. Model predictions are validated against independent murine data involving navitoclax and anti-PD-L1 treatment. The model is used to study different strategies of combining the senolytic drug with anti-PD-L1, in order to maximize the remission time of the combined treatment. The optimal starting time of the treatment with the senolytic drug depends on the senescent-to-functional T cells ratio, Ts/T. The paper identifies immune senescence as an important determinant of response to cancer immunotherapy.
Source: PLoS ONE
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,382
OpenAlex ID: W7236784601
FWCI:
Cites: 63
Cited by:
Related to: 10
Parts: 17